

# HPLC as a Complimentary Technique to Quantify Bevacizumab

Cristina Pangua<sup>1</sup>, Socorro Espuelas, PhD<sup>1</sup>, Juan M. Irache, PhD<sup>1</sup>, Mandana Fasth<sup>2</sup>, Iñaki Gorostiza<sup>2</sup>, and Bryan Tackett, PhD<sup>3</sup>

<sup>1</sup>University of Navarra, Department of Chemistry and Pharmaceutical Technology, C/Irunlarrea, 1, Pamplona 31008, Navarra, Spain

<sup>2</sup>Phenomenex Spain, C/Valgrande, 8, Edificio Thanworth II Planta 2.1.B, 28108 Alcobendas, Spain

<sup>3</sup>Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

## Overview

Bevacizumab is a monoclonal antibody used as an immunotherapy for several types of cancers. One common technique to quantify monoclonal antibodies (mAb) is the use of Enzyme-Linked Immunosorbent Assay (ELISA). ELISA offers some advantages, including a high selectivity and sensitivity and the possibility to perform analysis without complicated sample pre-treatment. However, it is very labor intensive and its elevated cost and relatively short expiration date due to antibody instability limits its use in routine analytical quantification. There is also a high potential for false positive/negative results which leads to variability and low confidence in those results. In many instances there is inadequate inhibition of immunogenic antigens due to cross reactivity, leading to weak (or low) signal intensity.

High-performance Liquid Chromatography (HPLC) alleviates many of the common challenges associated with ELISA. It is a simpler technique that typically has a shorter total time for analysis. Compared to ELISA, HPLC is low-cost, more reproducible, and more sensitive, providing more reliable results. As such, HPLC is a more suitable tool in discovery, development, and manufacturing environments.

Employing an HPLC method allowed us to evaluate the capability of albumin-based nanoparticles to encapsulate Bevacizumab, to study its release from these nanoparticles in simulated physiological media and show adequate separation between peaks from Human Serum Albumin (HSA) (65 kDa) and Bevacizumab (150 kDa). In this application note, we provide a simple, rapid, and low-cost method for the quantification of Bevacizumab formulated in HSA-based nanoparticles using a Biozen 3  $\mu$ m dSEC-2 HPLC Column. The bioinert hardware and hydrophilic surface chemistry of the Biozen dSEC-2 column offers sufficient resolution to reliably separate and quantify both Bevacizumab and HSA reproducibly.

## LC Conditions

**Columns:** Biozen™ 3  $\mu$ m dSEC-2

**Dimensions:** 300 x 4.6 mm

**Part No.:** [00H-4788-E0](#)

**Mobile Phase:** 35 mM Phosphate Buffer + 300 mM NaCl, pH 6.8

**Flow Rate:** 0.2 mL/min (Isocratic)

**Injection Volume:** 10  $\mu$ L


**Temperature:** 25 °C

**Detector:** PDA @ 280 nm

**LC System:** Agilent® 1200 Series




**Figure 1.** 200 µg/mL HSA in an Aqueous Solution on Biozen™ 3 µm dSEC-2 Column.




Peak No.	Analyte	Retention Time (min)	Width	Area	Height
1	HSA	15.518	0.291	224.74	11.65

**Figure 2.** 200 µg/mL Bevacizumab in an Aqueous Solution on Biozen 3 µm dSEC-2 Column.




Peak No.	Analyte	Retention Time (min)	Width	Area	Height
1	Bevacizumab	14.534	0.345	846.44	37.01

**Figure 3.** 200 µg/mL HSA and 200 µg/mL Bevacizumab in an Aqueous Solution on Biozen 3 µm dSEC-2 Column.



Peak No.	Analyte	Retention Time (min)	Width	Area	Height
1	Bevacizumab	14.504	0.329	704.86	32.83
2	Human Serum Albumin	15.445	0.279	199.00	11.01

**Figure 4.** Bevacizumab Encapsulated in HSA Nanoparticles on Biozen 3 µm dSEC-2 Column.



Peak No.	Analyte	Retention Time (min)	Width	Area	Height
1	Bevacizumab	14.045	0.384	805.76	30.49
2	Human Serum Albumin	15.387	0.288	3113.16	163.40

**Table 1.** Comparison Between the Quantification of Bevacizumab by ELISA versus HPLC.

	ELISA	HPLC
Lowest limit of quantification	30 ng/mL	12.5 µg/mL
Total time for analysis (min)	70	17
Sample numbers	96	Depends on the lifetime of the column (~1000 injections)
Bevacizumab loading (µg Bevacizumab/mg formulation)*	26 ± 4	28 ± 2

\*Data expressed as Mean ± SD, n=10.



**Need a different column size or sample preparation format?**

No problem! We have a majority of our available dimensions up on [www.phenomenex.com](http://www.phenomenex.com), but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal [www.phenomenex.com/Chat](http://www.phenomenex.com/Chat).

**Australia**

t: +61 (0)2-9428-6444  
auinfo@phenomenex.com

**Austria**

t: +43 (0)1-319-1301  
anfrage@phenomenex.com

**Belgium**

t: +32 (0)2 503 4015 (French)  
t: +32 (0)2 511 8666 (Dutch)  
beinfo@phenomenex.com

**Canada**

t: +1 (800) 543-3681  
info@phenomenex.com

**China**

t: +86 400-606-8099  
cninfo@phenomenex.com

**Czech Republic**

t: +420 272 017 077  
cz-info@phenomenex.com

**Denmark**

t: +45 4824 8048  
nordicinfo@phenomenex.com

**Finland**

t: +358 (0)9 4789 0063  
nordicinfo@phenomenex.com

**France**

t: +33 (0)1 30 09 21 10  
franceinfo@phenomenex.com

**Germany**

t: +49 (0)6021-58830-0  
anfrage@phenomenex.com

**Hong Kong**

t: +852 6012 8162  
hkinfo@phenomenex.com

**India**

t: +91 (0)40-3012 2400  
indiainfo@phenomenex.com

**Indonesia**

t: +62 21 5019 9707  
indoinfo@phenomenex.com

**Ireland**

t: +353 (0)1 247 5405  
eireinfo@phenomenex.com

**Italy**

t: +39 051 6327511  
italiainfo@phenomenex.com

**Japan**

t: +81 (0) 120-149-262  
jpinfo@phenomenex.com

**Luxembourg**

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

**Mexico**

t: 01-800-844-5226  
tecnicomx@phenomenex.com

**The Netherlands**

t: +31 (0)30-2418700  
nlinfo@phenomenex.com

**New Zealand**

t: +64 (0)9-4780951  
nzinfo@phenomenex.com

**Norway**

t: +47 810 02 005  
nordicinfo@phenomenex.com

**Poland**

t: +48 22 104 21 72  
pl-info@phenomenex.com

**Portugal**

t: +351 221 450 488  
ptinfo@phenomenex.com

**Singapore**

t: +65 6559 4364  
sginfo@phenomenex.com

**Slovakia**

t: +420 272 017 077  
sk-info@phenomenex.com

**Spain**

t: +34 91-413-8613  
espinfo@phenomenex.com

**Sweden**

t: +46 (0)8 611 6950  
nordicinfo@phenomenex.com

**Switzerland**

t: +41 (0)61 692 20 20  
swissinfo@phenomenex.com

**Taiwan**

t: +886 (0) 0801-49-1246  
twinfo@phenomenex.com

**Thailand**

t: +66 (0) 2 566 0287  
thaiinfo@phenomenex.com

**United Kingdom**

t: +44 (0)1625-501367  
ukinfo@phenomenex.com

**USA**

t: +1 (310) 212-0555  
[www.phenomenex.com/chat](http://www.phenomenex.com/chat)

**🌐 All other countries/regions  
Corporate Office USA**

t: +1 (310) 212-0555  
[www.phenomenex.com/chat](http://www.phenomenex.com/chat)

**www.phenomenex.com**

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at [international@phenomenex.com](mailto:international@phenomenex.com)

**BE-HAPPY™  
GUARANTEE**

Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

[www.phenomenex.com/behappy](http://www.phenomenex.com/behappy)

**Terms and Conditions**

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at [www.phenomenex.com/phx-terms-and-conditions-of-sale](http://www.phenomenex.com/phx-terms-and-conditions-of-sale).

**Trademarks**

Biozen and BE-HAPPY are trademarks of Phenomenex. Agilent is a registered trademark of Agilent Technologies, Inc.

**Disclaimer**

Comparative separations may not be representative of all applications. Phenomenex is in no way affiliated with Agilent Technologies, Inc.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2023 Phenomenex, Inc. All rights reserved.

